Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

OKUR vs CBIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CBIO Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–2 Matrix Metrics)

CBIO Overall Winner 6-Pillar Tally: OKUR 2 – 3 CBIO (1 Tie) Matrix Metrics: OKUR 2 – 4 CBIO

As of Nov 20, 2026, Crescent Biopharma, Inc. (CBIO) is the stronger overall head-to-head candidate over OnKure Therapeutics, Inc. (OKUR) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). OKUR carries a Unified Composite Score of 36.0/100 (SELL) at $2.70 (N/M Forward P/E, 0.0% operating margin), whereas CBIO carries 49.2/100 (HOLD) at $13.00 (N/M Forward P/E, -1228.4% operating margin).

  • Technical & Structure Timing Caution: OKUR is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.7); meanwhile CBIO is in a Breakdown options structure phase (RSI 45.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OKUR vs CBIO
OKUR NASDAQ
OnKure Therapeutics, Inc. Class A Common Stock
Pharmaceutical Preparations
$2.70
-2.17% 1D
Market Cap $113.7M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.96β · 100% Vol
Unified Composite Score
36.0 / 100 SELL
Tech 20.0 Fund 46.0 Flow 64.0 Mom 60.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -12.6%) with fading momentum, RSI 49
RSI-14: 48.7 · SMA20: $2.76 · SMA50: $2.67
CBIO NASDAQ Head-to-Head Winner
Crescent Biopharma, Inc. Common Stock
Pharmaceutical Preparations
$13.00
+0.7% 1D
Market Cap $539.5M
TTM Revenue $15M
Forward P/E N/M
Beta / 30D Vol 1.18β · 60% Vol
Unified Composite Score
49.2 / 100 HOLD
Tech 45.0 Fund 56.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 45.1 · SMA20: $13.45 · SMA50: $14.10

6-Pillar Scorecard Institutional Category Breakdown (OKUR 2 – 3 CBIO)

Columns: Metric · OKUR · CBIO
1. Valuation Multiples CBIO
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 16.8x
2. Growth & Scale CBIO
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $15M
Market Cap $113.7M $539.5M
3. Profitability & Quality OKUR
Gross Margin N/A 100.0%
Operating Margin 0.0% -1228.4%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -55.2% -160.8%
4. Balance Sheet & Cash Flow OKUR
Cash Generation (TTM) -$48M -$162M
Cash Flow Margin N/A N/A
Net Cash / Leverage $151M Net Cash $287M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CBIO
Options Structure Phase SURGE BREAKDOWN
Current IV / %ile 89.1% (100th %ile) 215.9% (98th %ile)
Put/Call OI Skew N/A 1.00x (Balanced)
OBV Trend / Tech Phase DISTRIBUTION · Distribution DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OKUR (2) vs CBIO (4)
Institutional Metric OKUR CBIO Criterion Row Edge
Market Capitalization
Scale
$113.7M $539.5M Larger Scale CBIO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% -1228.4% Higher Margin OKUR
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-55.2% -160.8% Higher ROE OKUR
52-Week Range Position
Momentum
20% ($2–$5) 23% ($9–$27) Stronger Trend CBIO
Beta / 30D Volatility
Risk Regime
0.96β · 100% Vol 1.18β · 60% Vol Lower Realized Risk CBIO
Unified Institutional Score
Composite Signal
36.0 / 100 (SELL) 49.2 / 100 (HOLD) Higher Composite CBIO
Trailing 12M Revenue (USD)
Operating Scale
N/A $15M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 16.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$48M ($151M Net Cash) -$162M ($287M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OKUR +5.72 pp
OKUR: +4.65% · CBIO: -1.07%
3M Horizon CBIO +7.2 pp
OKUR: -30.59% · CBIO: -23.39%
6M Horizon OKUR +1.45 pp
OKUR: -35.87% · CBIO: -37.32%
1Y Horizon CBIO +1.94 pp
OKUR: -2.17% · CBIO: -0.23%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OKUR vs CBIO. Trailing 12-month operating profitability (OKUR 0.0% vs CBIO -1228.4%) and valuation multiples (OKUR N/M vs CBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

OKUR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-55.2% · N/M
CBIO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$15M
Gross Margin100.0%
Op. Margin-1228.4%
ROE / Fwd P/E-160.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OKUR SURGE
8d in phase · OBV DISTRIBUTION
Current IV 89.1%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact OKUR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CBIO BREAKDOWN
148d in phase · OBV DISTRIBUTION
Current IV 215.9%
IV Percentile 98th %ile
Put/Call OI Skew 1.00x (Balanced)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact CBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OKUR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $113.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $539.5M market capitalization and -1228.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OKUR vs CBIO Key Questions & Quantitative Answers

As of Nov 20, 2026, Crescent Biopharma, Inc. (CBIO) is the stronger overall head-to-head candidate over OnKure Therapeutics, Inc. (OKUR) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). OKUR carries a Unified Composite Score of 36.0/100 (SELL) at $2.70 (N/M Forward P/E, 0.0% operating margin), whereas CBIO carries 49.2/100 (HOLD) at $13.00 (N/M Forward P/E, -1228.4% operating margin). Technical & Structure Timing Caution: OKUR is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.7); meanwhile CBIO is in a Breakdown options structure phase (RSI 45.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CBIO leads the Growth & Scale pillar: OKUR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CBIO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $15M TTM revenue (100.0% gross margin, -1228.4% operating margin). On trailing 12-month operating scale, OKUR generates N/A in USD-normalized revenue versus $15M for CBIO. In operating R&D and SG&A reinvestment, OKUR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CBIO.

CBIO screens cheaper on headline valuation multiples. OKUR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OKUR (-55.2% ROE) versus CBIO (-160.8% ROE) capital efficiency.

In options market volatility and institutional positioning, OKUR carries 89.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.96β · 100% Vol realized risk). By comparison, CBIO carries 215.9% implied volatility (98th %ile, Extreme (>80th %ile)), a 1.00x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.18β · 60% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.